Nanologica AB (4YD) AI Stock Analysis

Nanologica AB

(Frankfurt:4YD)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRapid TTM revenue growth indicates improving commercial traction for Nanologica’s offerings. If this momentum continues through customer adoption and scale-up, it can expand the revenue base and provide operating leverage as the company develops recurring pharmaceutical and life-science demand.

Negative Factors

Persistent Operating LossesNegative gross and operating profit show that the current revenue base does not yet cover product costs and operating expenses. Until the business improves pricing, production economics, or scale, revenue growth may not translate into sustainable operating profitability or internally funded expansion.

Nanologica AB (4YD) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.93M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.5
Beta (1Y): 14.88
Revenue Growth: 174.91%
EPS Growth: ―
Country: Germany
Employees: 72
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Nanologica AB Business Overview & Revenue Model

Company Description

Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica fo...

Nanologica AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4YD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	80Outperform	SEK 40.76B	59.09	15.54%	―	<0.01%	-6.75%
SE:XBRANE	53Neutral	SEK 291.57M	-5.90	-13.41%	―	-38.80%	-120.18%
SE:NANEXA	52Neutral	SEK 1.97B	-76.50	-22.38%	―	104.76%	37.08%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SPAGO	43Neutral	SEK 32.09M	-0.85	-106.23%	―	-97.37%	25.28%
SE:XSPRAY	41Neutral	SEK 559.52M	-3.06	-26.00%	―	―	44.46%

* Healthcare Sector Average

Performance Comparison

DE:4YD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4YD	Nanologica AB	0.01	-0.07	-85.71%
SE:CAMX	Camurus AB	673.00	46.00	7.34%
SE:XBRANE	Xbrane Biopharma AB	14.15	3.35	31.02%
SE:XSPRAY	Xspray Pharma AB	11.80	-12.80	-52.04%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.11	-72.79%
SE:NANEXA	Nanexa AB	10.32	8.51	470.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Nanologica AB AI Stock Analysis